Inhibitor Therapeutics, Inc. (INTI) Total liabilities 2016–2021
Inhibitor Therapeutics, Inc. (INTI) total liabilities at each fiscal year-end, per SEC filings.
$3.7MFY2021 · since FY2016: $308,133 → $3.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2021 | $3.7M | +5.4% |
| FY2020 | $3.5M | +1.8% |
| FY2019 | $3.4M | +185.8% |
| FY2018 | $1.2M | +99.6% |
| FY2017 | $601,489 | +95.2% |
| FY2016 | $308,133 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More INTI financial trends
INTI RevenueINTI Net incomeINTI Net marginINTI Gross profitINTI Gross marginINTI Operating incomeINTI Operating marginINTI Operating cash flowINTI Free cash flowINTI Capital expendituresINTI Return on equityINTI Stock buybacksINTI Dividends paidINTI Total assetsINTI Shareholders’ equityINTI overview →